ATI RN
ATI Pharmacology Proctored Exam 2024
1. A healthcare professional is reviewing the medical record of a client with a new prescription for Epoetin Alfa. Which of the following findings should the professional report to the provider?
- A. The client has a history of hypertension.
- B. The client has a hemoglobin level of 10 g/dL.
- C. The client has a history of chronic kidney disease.
- D. The client has a blood pressure of 140/90 mm Hg.
Correct answer: C
Rationale: The correct answer is C. Chronic kidney disease is a contraindication for the use of Epoetin Alfa because it can worsen hypertension, increase the risk of cardiovascular events, and lead to adverse outcomes. Epoetin Alfa is used to treat anemia by stimulating red blood cell production, but in the presence of chronic kidney disease, it can exacerbate hypertension and contribute to cardiovascular complications. Choices A, B, and D are not directly related to the contraindication of Epoetin Alfa in the presence of chronic kidney disease.
2. A client has a new prescription for Levodopa/Carbidopa for Parkinson's disease. Which of the following instructions should the nurse include?
- A. Increase intake of protein-rich foods.
- B. Expect muscle twitching to occur.
- C. Take this medication with food.
- D. Anticipate relief of manifestations in 24 hours.
Correct answer: C
Rationale: The correct instruction for the nurse to include is to advise the client to take Levodopa/Carbidopa with food. This recommendation helps reduce gastrointestinal side effects commonly associated with this medication. Food can help minimize nausea and other stomach-related issues that may occur when taking Levodopa/Carbidopa. Options A, B, and D are incorrect. Increasing intake of protein-rich foods is not necessary with this medication. Muscle twitching is not an expected side effect of Levodopa/Carbidopa. Anticipating relief of manifestations in 24 hours is unrealistic as it may take days to weeks for the full therapeutic effect of the medication to be achieved.
3. A healthcare provider is reviewing the health care record of a client who is asking about conjugated equine estrogens. The healthcare provider should inform the client this medication is contraindicated in which of the following conditions?
- A. Atrophic vaginitis
- B. Dysfunctional uterine bleeding
- C. Osteoporosis
- D. Thrombophlebitis
Correct answer: D
Rationale: Conjugated equine estrogens are contraindicated in individuals with a history of thrombophlebitis due to the increased risk of thrombotic events associated with estrogen use. Thrombophlebitis is a condition characterized by inflammation and blood clot formation in the veins, and estrogen therapy can exacerbate this condition, leading to serious complications such as deep vein thrombosis. Therefore, caution is advised when considering estrogen therapy in clients with a history of thrombophlebitis to prevent adverse outcomes. Choices A, B, and C are not contraindications for conjugated equine estrogens. Atrophic vaginitis and dysfunctional uterine bleeding may actually be conditions for which estrogen therapy is indicated. Osteoporosis can also be managed with estrogen therapy in certain cases to help prevent bone density loss.
4. A client has a new prescription for Hydralazine. Which of the following adverse effects should the nurse instruct the client to monitor?
- A. Tachycardia
- B. Hyperglycemia
- C. Hyponatremia
- D. Constipation
Correct answer: A
Rationale: Corrected Rationale: Hydralazine is a vasodilator that can cause reflex tachycardia as an adverse effect. The client should monitor their pulse and report any significant increases, as tachycardia can indicate a severe adverse reaction to the medication. Choice B, Hyperglycemia, is not a common adverse effect of Hydralazine. Choice C, Hyponatremia, and Choice D, Constipation, are also not typically associated with Hydralazine use. Therefore, the correct answer is A: Tachycardia.
5. A healthcare professional is educating a client who is starting therapy with gemcitabine. Which of the following findings should the healthcare professional instruct the client to report?
- A. Dyspnea
- B. Constipation
- C. Tinnitus
- D. Dry mouth
Correct answer: A
Rationale: The healthcare professional should instruct the client to report dyspnea since it can indicate pulmonary toxicity, a severe adverse effect associated with gemcitabine therapy. Monitoring and reporting dyspnea promptly can help in early detection and management of potential serious complications. Constipation, tinnitus, and dry mouth are not typically associated with gemcitabine therapy and are not urgent findings requiring immediate reporting.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access